| 1 | 1/1 | 返回列表 |
| 查看: 1029 | 回復(fù): 0 | |||
[交流]
美國MD Anderson 招聘博后
|
|
胡建實(shí)驗(yàn)室致力于中樞神經(jīng)系統(tǒng)中的干細(xì)胞和神經(jīng)膠質(zhì)學(xué)研究,尤其在神經(jīng)膠質(zhì)瘤和神經(jīng)退行性疾病方面取得重要成就。目前,實(shí)驗(yàn)室正在尋求志同道合之士加入,以進(jìn)一步探究調(diào)控中樞神經(jīng)系統(tǒng)腫瘤病變進(jìn)程的分子機(jī)制,并開發(fā)新的臨床治療靶點(diǎn)和藥物。 研究方向 惡性神經(jīng)膠質(zhì)瘤是原發(fā)性腦腫瘤中最常見和最致命的類型。大量證據(jù)表明,神經(jīng)干細(xì)胞 (NSC) 樣神經(jīng)膠質(zhì)瘤干細(xì)胞 (GSC) 群體具有無窮無盡的自我更新能力,是神經(jīng)膠質(zhì)瘤的“根”。與 NSC一樣,GSC 通過與生態(tài)位相互作用來維持其干性,這提供了適當(dāng)?shù)难芯克悸芬宰柚笹SC的分化,從而延緩神經(jīng)膠質(zhì)瘤的病變進(jìn)程。我們研究的一個(gè)方向是破譯 GSC 如何在生態(tài)位外的次優(yōu)環(huán)境中維持其自我更新能力的機(jī)制,尤其是入侵和遷移過程。 研究表明,惡性神經(jīng)膠質(zhì)瘤中的大多數(shù)免疫細(xì)胞是神經(jīng)膠質(zhì)瘤相關(guān)髓樣 (GAM) 細(xì)胞。 盡管 GAM 細(xì)胞具有良好的治療潛力,但人們對其在腫瘤發(fā)生過程中抑制轉(zhuǎn)化的分子機(jī)制知之甚少。因此,胡實(shí)驗(yàn)室研究的第二個(gè)方向是試圖填補(bǔ) GAM 細(xì)胞如何從抗腫瘤狀態(tài)轉(zhuǎn)化為促腫瘤狀態(tài)的知識(shí)空白,并開發(fā)合理的免疫治療干預(yù)措施來逆轉(zhuǎn) GAM 細(xì)胞的免疫抑制和促腫瘤極化。 胡實(shí)驗(yàn)室研究的第三個(gè)方向是尋找脫髓鞘疾病/病癥的新治療方法,例如多發(fā)性硬化癥和化療引起的神經(jīng)缺陷(Chemo-Brain)。髓磷脂是一種特殊的多層膜結(jié)構(gòu),由少突膠質(zhì)細(xì)胞或施旺細(xì)胞組裝而成。脫髓鞘疾病/病癥是髓鞘和/或少突膠質(zhì)細(xì)胞受損的獲得性病癥。我們最近對成熟髓鞘的研究有了驚人的發(fā)現(xiàn),即成熟髓鞘是一種非常有活力的物質(zhì),其脂質(zhì)成分可以快速更新。目前,我們正在嘗試開發(fā)新方法來恢復(fù)脫髓鞘疾病/病癥中的脂質(zhì)代謝。 職位要求 申請者應(yīng)具有生物相關(guān)博士學(xué)位,并具有神經(jīng)科學(xué)、癌癥生物學(xué)、神經(jīng)免疫學(xué)、代謝組學(xué)、遺傳學(xué)或生物化學(xué)等方面的經(jīng)驗(yàn);有科研熱情,有進(jìn)取心,具備良好的溝通能力和團(tuán)隊(duì)協(xié)作精神;以第一作者發(fā)表過SCI論文者優(yōu)先。 職位待遇 按照NIH標(biāo)準(zhǔn)執(zhí)行,詳情見鏈接:https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-132.html。 特色與優(yōu)勢 美國MD安德森癌癥中心,始建于1941年,位于美國南部德克薩斯州的休斯頓市,是一所世界一流的癌癥研究、診治中心。自1990年以來,一直居“美國最佳醫(yī)院排行榜”中腫瘤科的前2位,連續(xù)5年在美國癌癥研究醫(yī)院評比中排名第一。由于其在癌癥研究與臨床方面的驕人業(yè)績,逐漸成為全球最具影響力的腫瘤中心。MD安德森擁有充足的科研經(jīng)費(fèi),其在國家癌癥研究所獲資助數(shù)量中排名第一,在MD Anderson,可以感受到無與倫比的科研環(huán)境,博士生以及博后均可獲得良好的科研訓(xùn)練。 MD安德森所在的城市——休斯頓,是美國得克薩斯州的第一大城,全美國第四大城市,墨西哥灣沿岸最大的經(jīng)濟(jì)中心。休斯頓以其能源(特別是石油)、航空工業(yè)和運(yùn)河聞名世界,有“太空城”之美譽(yù);此外,休斯頓氣候宜人,環(huán)境優(yōu)美,被列為全美十大綠色城市之一,人均綠化面積僅次于圣地亞哥,排名第二。由于眾多的工作機(jī)會(huì)以及低廉的生活成本,休斯頓深受各地移民者的青睞。 在此,我們誠邀有志之士加入,我們將提供穩(wěn)定的工作環(huán)境和一流的研究平臺(tái),希望應(yīng)聘者具備鉆研精神,能夠腳踏實(shí)地的探索科學(xué)問題并且勇于嘗試新的研究方向。有意向者請發(fā)送個(gè)人簡歷到 jhu3@mdanderson.org。 胡實(shí)驗(yàn)室的主頁: https://www.mdanderson.org/research/departments-labs-institutes/labs/hu-laboratory/research.html The Jian Hu laboratory at MD Anderson Cancer Center is seeking outstanding and motivated postdoctoral candidates to expand our work on molecular mechanisms underpinning brain tumor development and glia functions (Hu J., et al., Cell 2012; Shingu T., et al., Nature Genetics2017; Zhou X., et al., JCI 2020, Ren J., et al., JEM2021, Shin S., et al., Nature Communications2021, Zhou X., eLife 2021). We are particularly interested in strengthening three aspects of our research. The first is to decipher the mechanisms of how glioma stem cells (GSCs) manage to sustain their self-renewal capacity in the sub-optimal environment outside the niches, particularly during the process of invasion and migration. The second is to fill the knowledge gap of how glioma associated microglia/macrophages (GAMs) are converted from the antitumor to pro-tumor state and develop rational immunotherapeutic interventions to reverse immune-suppressive, tumor-promoting polarization of GAMs. Lastly, we are looking for new therapeutic approaches for demyelinating diseases such as multiple sclerosis and chemotherapy-induced neurological defects (chemo-brain). Qualified candidates should have strong background in one or more of the following areas: neuroscience, cancer biology, neuroimmunology, metabolism, genetics, or biochemistry. We are only interested in the candidates who are committed to ask fundamentally important questions and are fearless in trying novel approaches. A track record of excellent first author publication during PhD training is essential. The pay scale follows NIH guidelines ($54,840 for fresh PhD with adjustment for more senior candidates). MD Anderson is the number one cancer center in cancer care in the United States by the U.S. News and World Report’s “America’s Best Hospitals” survey. It ranks 1st in the number of awarded grants from National Cancer Institute. It offers active graduate and postdoctoral training programs and the unmatched scientific environment of the Texas Medical Center, the world’s largest biomedical center. MD Anderson is an equal opportunity/affirmative action employer. Houston is the 4th largest city in the United States with relatively low living cost and no state or city income tax. The interested candidates should send a CV to jhu3@mdanderson.org. 發(fā)自小木蟲IOS客戶端 |
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 一志愿211,0860總分286食品工程專業(yè)求調(diào)劑 +4 | 林林Winnie 2026-03-05 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 材料調(diào)劑 +5 | ws 上岸鴨 2026-03-05 | 5/250 |
|
|
[考研] 材料調(diào)劑 +4 | L9370 2026-03-05 | 4/200 |
|
|
[考研] 歡迎采礦、地質(zhì)、巖土、計(jì)算機(jī)、人工智能等專業(yè)的同學(xué)報(bào)考 +10 | pin8023 2026-02-28 | 13/650 |
|
|
[考研] 材料學(xué)碩318求調(diào)劑 +19 | February_Feb 2026-03-01 | 21/1050 |
|
|
[考研] 290求調(diào)劑 +5 | Bananaiy 2026-03-04 | 5/250 |
|
|
[考博] 申博 +3 | 添菜了哈 2026-03-04 | 5/250 |
|
|
[考研] 283求調(diào)劑 +10 | 鹿沫笙 2026-03-02 | 11/550 |
|
|
[考研] 085600材料調(diào)劑 總分330 +5 | 池池丶 2026-03-03 | 5/250 |
|
|
[考研] 267調(diào)劑求助 +5 | 聰少OZ 2026-03-04 | 5/250 |
|
|
[考研] 304分材料專碩求調(diào)劑 +11 | qiuzhigril 2026-03-03 | 14/700 |
|
|
[考研] 070300化學(xué) 280 一志愿太原理工 求調(diào)劑 +8 | 拾玖壹 2026-03-04 | 8/400 |
|
|
[論文投稿]
100+4
|
Stray2021 2026-03-03 | 4/200 |
|
|
[考研]
|
旅行中的紫葡萄 2026-03-03 | 4/200 |
|
|
[考研] 298求調(diào)劑一志愿中海洋 +3 | lour. 2026-03-03 | 3/150 |
|
|
[考研] 085600材料與化工調(diào)劑 280分 +10 | yyqqhh 2026-03-03 | 10/500 |
|
|
[考研] 276求調(diào)劑 +8 | 路lyh123 2026-02-28 | 10/500 |
|
|
[考研] 284求調(diào)劑 +6 | 天下熯 2026-03-02 | 6/300 |
|
|
[考研] 化工京區(qū)271求調(diào)劑 +7 | 11ing 2026-03-02 | 7/350 |
|
|
[考研] 085600材料工程一志愿中科大總分312求調(diào)劑 +9 | 吃宵夜1 2026-02-28 | 11/550 |
|